Radiographic repair in three Japanese patients with rheumatoid arthritis treated with bucillamine

References

• Nanke Y, Kotake S, Akama H, Kamatani N. Alkaline phospha-tase in rheumatoid arthritis patients: possible contribution of bone type ALP to the raised activities of ALP in rheumatoid arthritis patients. Clin Rheumatol. 2002;21:198–202.
   PubMed Web of Science ®Google Scholar
• Niino-Nanke Y, Akama H, Hara M, Kashiwazaki S. Alkaline phosphatase (ALP) activity in rheumatoid arthritis (RA): its clinical significance and synthesis of ALP in RA synovium. Riumachi. 1998;38:5–12.
   Google Scholar
• Suda A, Nagaoka S, Ohono S, Ideguchi H, Soga T, Ishigatsubo Y. The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study. Mod Rheumatol. 2008;18:609–14.
   PubMed Web of Science ®Google Scholar
• Nanke Y, Yamada T, Kamatani N. Asymptomatic interstitial pneumonia induced by bucillamine in a patient with rheumatoid arthritis. Mod Rheumatol. 2005;15:381–2.
   Google Scholar
• Iwatani M, Inoue E, Nakamura T, Nakajima A, Hara M, Tomatsu T, et al. Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. Mod Rheum. 2006;16:376–80.
   PubMedGoogle Scholar
• Yamamoto I, Ohmori H, Ohmura T. 5A96: an immunophar-macological profile in vitro. Int J. Tissue React. 1982;IV(1):1–8.
   Google Scholar
• Eguchi K, Kawakami A, Ida H, Nakashima M, Yamashita I, Sakai M, et al. Bucillamine inhibits T cell adhesion to human endothelial cells. J Rheumatol. 1992;19:1045–50.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Lipsky PE. Immunosuppression by the disease modifying antirheumatic drug bucillamine: inhibition of human T lymphocyte function by bucillamine and its metabolites. J Rheumatol. 1993;20:953–7.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Lipsky PE. Regulation of B cell function by bucill-amine, a novel disease-modifying antirheumatic drug. Clin Immunol Immunopathol. 1993;66:43–51.
   PubMedGoogle Scholar
• Aono H, Hasunuma T, Fujisawa K, Nakajima T, Yamamoto K, Mita S, et al. Direct suppression of human synovial cell prolif-eration in vitro by salazosulfapyridine and bucillamine. J Rheu-matol. 1995;22:65–70.
   Google Scholar
• Matsuno H, Sugiyama E, Muraguchi A, Nezuka T, Kubo T, Matsuura K, et al. Pharmacological effects of 5A96 (bucillamine) and its metabolites as immunomodulating drugs-the disulfide structure of SA-96 metabolites plays a critical role in the phar-macological action of the drug. Int J. Immunopharmacol. 1998;20:295–304.
   PubMed Web of Science ®Google Scholar
• Shiokawa Y, Ogawa T, Abe T, Kosaka S, Honma M, Akizuki M, et al. Evaluation of drug efficacy of 5A96 on rheumatoid arthritis-multicenter double-blinded comparative study. J C E Med. 1985;135(12,13):1116–33.
   Google Scholar
• Rau R, Wassenberg S, Herborn G, Thomas W, Perschel T, Fre-itag G. Identification of radiologic healing phenomena in patients with rheumatoid arthritis. J Rheumatol. 2001;12:2608–15.
   Google Scholar
• Sharp JT, Heijde D, Boers M, Boonen A, Bruynesteyn K, Emery P, et al. Repair of erosions in rheumatoid arthritis does occur: results from two studies by the OMERACT subcommittee on healing of erosions. J Rheumatol. 2003;30:1102–7.
   PubMed Web of Science ®Google Scholar
• McCarty DJ. Clinical picture of rheumatoid arthritis. In: McCarty DJ, editor. Arthritis and allied conditions. 11th ed. Philadelphia: Lea and Febiger; 1989.
   Google Scholar
• Ideguchi H, Ohno S, Hattori H, Senuma K, Ishigatsubo Y. Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying anti-rheumatic drugs. Arthrits Res Ther. 2006;8(3):R76.
   Google Scholar
• St. Clair EW, Heijde DMFM, Smolen JS, Maim RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum. 2004;50:3432–43.
   PubMed Web of Science ®Google Scholar
• Klareskon L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. TEMPO (trial of etanercept and methotrexate with radiographic patient outcome) study investigators: thera-peutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blinded randomized controlled trial. Lancet. 2004;363:675.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanugh AF, Sharp JT, Tanenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. A randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50: 1400–11.
   Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study or active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.
   PubMed Web of Science ®Google Scholar
• Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103(9):1345–52.
   PubMed Web of Science ®Google Scholar
• Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 2001;44(5): 1003–12.
   PubMed Web of Science ®Google Scholar
• Suematsu A, Tajiri Y, Nakashima T, Taka J, Ochi S, Nakamura K, et al. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis. Mod Rheumatol. 2007;17:17–23.
   PubMedGoogle Scholar
• Redlich K, Gortz B, Hayer S, Zwerina J, Doerr N, Kostenuik P, et al. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol. 2004;164:543–55.
   PubMed Web of Science ®Google Scholar